KZR Average Annual Return Since 2018
Growth of $10,000.00
Without Dividends Reinvested Into KZR


Also see:
KZR stock yearly return 2019
KZR stock yearly return 2020
KZR stock yearly return 2021
KZR stock yearly return 2022
KZR stock yearly return 2023
KZR YTD return
Compare KZR average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/22/2018
End date: 06/24/2024
Start price/share: $17.79
End price/share: $0.65
Dividends collected/share: $0.00
Total return: -96.35%
KZR Average Annual Return: -42.34%
Starting investment: $10,000.00
Ending investment: $365.28
Years: 6.01


KZR average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Co.'s primary product candidate, KZR-616, is a selective immunoproteasome inhibitor. KZR-261 is the main clinical candidate from Co.'s research platform targeting the Sec61 translocon and the protein secretion pathway for the discovery and development of small molecule therapeutics for oncology and autoimmune indications. KZR-261 has demonstrated anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival. The KZR average annual return since 2018 is shown above.

The Average Annual Return on the KZR average annual return since 2018 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether KZR average annual return since 2018 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the KZR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree KZR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kezar Life Sciences (KZR) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

LAB Average Annual Return
LBPH Average Annual Return
LEXX Average Annual Return
LFMD Average Annual Return
LFST Average Annual Return
LGND Average Annual Return
LGVN Average Annual Return
LH Average Annual Return
LIPO Average Annual Return
LIXT Average Annual Return
More Healthcare companies »

 

KZR Average Annual Return Since 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.